BMY started to test Nivolumab in hematologic malignancies already: http://clinicaltrials.gov/show/NCT01592370 I have seen preliminary data from PD1 in lymphoma last year. Signal isn't as clear as in melanoma/RCC/NSCLC, difficult to interpret.